|
1
|
Draper L: Breast cancer: Trends, risks,
treatments, and effects. AAOHN J. 54:445–451, quiz 452–453. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jepsen P, Vilstrup H, Tarone RE, Friis S
and Sørensen HT: Incidence rates of hepatocellular carcinoma in the
U.S. and Denmark: Recent trends. Int J Cancer. 121:1624–1626. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sirotnak FM, Zakowski MF, Miller VA, Scher
HI and Kris MG: Efficacy of cytotoxic agents against human tumor
xenografts is markedly enhanced by coadministration of ZD1839
(Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res.
6:4885–4892. 2000.PubMed/NCBI
|
|
4
|
Rao YK, Fang SH and Tzeng YM: Differential
effects of synthesized 2´-oxygenated chalcone derivatives:
Modulation of human cell cycle phase distribution. Bioorg Med Chem.
12:2679–2686. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bandgar BP, Gawande SS, Bodade RG, Totre
JV and Khobragade CN: Synthesis and biological evaluation of simple
methoxylated chalcones as anticancer, anti-inflammatory and
antioxidant agents. Bioorg Med Chem. 18:1364–1370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rao YK, Kao TY, Ko JL and Tzeng YM:
Chalcone HTMC causes in vitro selective cytotoxicity, cell-cycle G1
phase arrest through p53-dependent pathway in human lung
adenocarcinoma A549 cells, and in vivo tumor growth suppression.
Bioorg Med Chem Lett. 20:6508–6512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Roque A, Lima JC, Parola AJ and Pina F:
Substitution and solvent effects in the chalcones isomerization
barrier of flavylium photochromic systems. Photochem Photobiol Sci.
6:381–385. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iwata S, Nishino T, Inoue H, Nagata N,
Satomi Y, Nishino H and Shibata S: Antitumorigenic activities of
chalcones (II). Photo-isomerization of chalcones and the
correlation with their biological activities. Biol Pharm Bull.
20:1266–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin F, Giuliano AE, Law RE and Van Herle
AJ: Apigenin inhibits growth and induces G2/M arrest by modulating
cyclin-CDK regulators and ERK MAP kinase activation in breast
carcinoma cells. Anticancer Res. 21(1A): 1–420. 2001.PubMed/NCBI
|
|
10
|
Katiyar SK, Roy AM and Baliga MS:
Silymarin induces apoptosis primarily through a p53-dependent
pathway involving Bcl-2/Bax, cytochrome c release, and caspase
activation. Mol Cancer Ther. 4:207–216. 2005.PubMed/NCBI
|
|
11
|
León-González AJ, Acero N, Muñoz-Mingarro
D, Navarro I and Martín-Cordero C: Chalcones as promising lead
compounds on cancer therapy. Curr Med Chem. 22:3407–3425. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leydet Y, Batat P, Jonusauskas G, Denisov
S, Lima JC, Parola AJ, McClenaghan ND and Pina F: Impact of water
on the cis-trans photoisomerization of hydroxychalcones. J Phys
Chem A. 117:4167–4173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
El-Said MS, El-Gazzar MG, Al-Dosari MS and
Ghorab MM: Synthesis, anticancer activity and radiosensitizing
evaluation of some new 2-pyridone derivatives.
Arzneimittelforschung. 62:149–156. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buduma K, Chinde S, Arigari NK, Grover P,
Srinivas KV and Kotesh Kumar J: Iodine catalyzed simple and
efficient synthesis of antiproliferative 2-pyridones. Bioorg Med
Chem Lett. 26:2159–2163. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho M, Choi E, Yang JS, Lee C, Seo JJ, Kim
BS, Oh SJ, Kim HM, Lee K, Park SK, et al: Discovery of
pyridone-based histone deacetylase inhibitors: Approaches for
metabolic stability. ChemMedChem. 8:272–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu X, Zeng H, Zhu X, Ma Q, Hou Y and Wu X:
Novel pyrrolopyridinone derivatives as anticancer inhibitors
towards Cdc7: QSAR studies based on dockings by solvation score
approach. Eur J Pharm Sci. 50:323–334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan W, Huang Z, Wang Z, Cao S, Tong L,
Zhang T, Wang C, Zhou L, Ding J, Luo C, et al: Discovery of
1,3-Diaryl-pyridones as potent VEGFR-2 inhibitors: Design,
synthesis, and biological evaluation. Chem Biol Drug Des.
87:694–703. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lescoat G, Chantrel-Groussard K, Pasdeloup
N, Nick H, Brissot P and Gaboriau F: Antiproliferative and
apoptotic effects in rat and human hepatoma cell cultures of the
orally active iron chelator ICL670 compared to CP20: A possible
relationship with polyamine metabolism. Cell Prolif. 40:755–767.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Segreti JA, Polakowski JS, Koch KA, Marsh
KC, Bauch JL, Rosenberg SH, Sham HL, Cox BF and Reinhart GA: Tumor
selective antivascular effects of the novel antimitotic compound
ABT-751: An in vivo rat regional hemodynamic study. Cancer
Chemother Pharmacol. 54:273–281. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elmeligie S, Khalil NA, Ahmed EM and Emam
SH: New 3-substituted-2-(4-hydroxyanilino) pyridine derivatives:
Synthesis, antitumor activity and tubulin polymerization
inhibition. Arch Pharm (Weinheim). 350:3502017. View Article : Google Scholar
|
|
21
|
Agarwal ML, Taylor WR, Chernov MV,
Chernova OB and Stark GR: The p53 network. J Biol Chem. 273:1–4.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shimokawa N, Qiu CH, Seki T, Dikic I and
Koibuchi N: Phosphorylation of JNK is involved in regulation of
H(+)-induced c-Jun expression. Cell Signal. 16:723–729. 2004.
View Article : Google Scholar : PubMed/NCBI
|
